Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension

Summary

The purpose of this study is to see if the drug sotatercept given for 36 weeks improves the functioning of the heart and improves quality of life.

Timeline

Start

2024-07-05

Primary completion

2026-01-14

Completion

2026-01-14

Outcome

Met primary endpoint

paper sotatercept improved the primary endpoint of peak exercise mean pulmonary artery PMID 41885673 ↗

paper peak exercise mean pulmonary artery (PA)/cardiac output (CO) (-2.1 mm Hg/L/min; 95% CI: -3.1 to -1.1 mm Hg/L/min; P = 0.0003). PMID 41885673 ↗

Publications

• Reddy YNV, Frantz RP, Miranda WR, Harada T, Kazui S, Borlaug BA. Sotatercept in Pulmonary Arterial Hypertension: Central, Hematologic, and Peripheral Mechanisms of Benefit. J Am Coll Cardiol. 2026 Mar 2:S0735-1097(26)05633-0. doi: 10.1016/j.jacc.2026.02.5103. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sotatercept	Protein / enzyme biologic	0.7 mg/kg	Subcutaneous

Indications